100% effective lenacapavir shot prevents HIV in late-stage trial of 2,000 African women and adolescents, marking a potential HIV prevention breakthrough.
Gilead Sciences' experimental twice-yearly shot, lenacapavir, was 100% effective in preventing HIV infections in a late-stage trial of 2,000 African women and adolescent girls, marking a potential breakthrough in HIV prevention. If confirmed in further trials and approved, lenacapavir could become an easier-to-use alternative to daily pills or bi-monthly injections. Gilead's stock surged as a result of the positive results.
June 20, 2024
5 Articles